珠海冠宇(688772.SH):榮獲國家科學技術進步獎二等獎
格隆匯11月4日丨珠海冠宇(688772.SH)公佈,2021年11月3日,國務院在北京人民大會堂召開了2020年度國家科學技術獎勵大會。公司參與完成的“高可靠長壽命鋰離子電池關鍵技術及產業化應用”項目獲得國家科學技術進步獎二等獎,公司董事長兼總經理徐延銘、核心技術人員李素麗分別作為該項目的主要完成人之一,同時獲得國家科學技術進步獎二等獎。
該項目面向國家重大戰略需求,從電極材料多尺度調控、電池結構一體化設計、製造工藝全流程構建3個層次着手,成功解決了高端鋰離子電池壽命與可靠性提升的國家重大難題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.